Education
About Us
Working with TipRanks
Follow Us
Santhera Pharmaceuticals Holding Ag (CH:SANN)
:SANN
Earnings Data
Report Date
Apr 23, 2026TBA (Not Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
―Last Year’s EPS
-0.74Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with significant market adoption of AGAMREE in Europe and the U.S., strong commercial rollout in China, and increased revenue guidance. However, challenges such as a considerable operating loss and the need for additional financing were also highlighted.Company Guidance
Strong AGAMREE Adoption in Key Markets
AGAMREE has achieved approximately 40% market share of steroid using DMD patients in Germany and Austria, with Austria exceeding 50% market share.
U.S. Market Performance
Catalyst reported H1 2025 sales of USD 49.4 million, on track to meet the full-year guidance of $100 million to $110 million, which would trigger a $12.5 million milestone payment to Santhera.
Successful Commercial Rollout in China
Sperogenix commenced non-reimbursed commercial rollout in China with over 250 patients, representing significant growth potential.
Increased Revenue Guidance
Santhera increased its revenue guidance for 2025, expecting revenues to exceed CHF 65 million to CHF 70 million due to strong market performances.
Santhera Pharmaceuticals Holding (CH:SANN) Earnings, Revenues Date & History
CH:SANN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CH:SANN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Sep 23, 2025 | CHF13.86 | CHF11.90 | -14.14% |
Apr 29, 2025 | CHF15.28 | CHF14.80 | -3.14% |
Sep 12, 2024 | CHF9.76 | CHF8.90 | -8.81% |
Apr 25, 2024 | CHF9.46 | CHF9.50 | +0.42% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Santhera Pharmaceuticals Holding Ag (CH:SANN) report earnings?
Santhera Pharmaceuticals Holding Ag (CH:SANN) is schdueled to report earning on Apr 23, 2026, TBA (Not Confirmed).
What is Santhera Pharmaceuticals Holding Ag (CH:SANN) earnings time?
Santhera Pharmaceuticals Holding Ag (CH:SANN) earnings time is at Apr 23, 2026, TBA (Not Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Santhera Pharmaceuticals Holding Ag stock?
The P/E ratio of Santhera Pharmaceuticals Holding is N/A.
What is CH:SANN EPS forecast?
Currently, no data Available